Guidare le aziende sanitarie nella crisi : il ruolo dei direttori generali : l'esperienza della Regione Lazio / Mario Del Vecchio, Anna Romiti

• Record Nr.: UNISA996492368103316
• Autore: DEL VECCHIO, Mario <1958- >
• Pubbl/distr/stampa: Milano, : EGEA, 2021
• ISBN: 978-88-238-4736-1
• Descrizione fisica: XIII, 122 p. ; 24 cm
• Collana: S&R
• Altri autori (Persone): ROMITI, Anna
• Disciplina: 362.10684
• Soggetti: Aziende sanitarie - Gestione - Casi [:] Lazio
• Collocazione: 362.106 DEL 1
• Lingua di pubblicazione: Italiano
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Note generali: In copertina: FIASO, Federazione italiana aziende sanitarie e ospedaliere

Imaging of inflammation and infection in cardiovascular diseases / / edited by Federico Caobelli

• Record Nr.: UNINA9910502664303321
• Pubbl/distr/stampa: Cham, Switzerland : , : Springer, , [2021]; ©2021
• ISBN: 3-030-81131-X
• Descrizione fisica: 1 online resource (274 pages)
• Disciplina: 616.12075
• Soggetti: Heart - Imaging; Heart - Infections; Malalties cardiovasculars; Malalties del cor; Diagnòstic per la imatge; Infeccions; Inflamació; Llibres electrònics
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Nota di bibliografia: Includes bibliographical references.
• Nota di contenuto: Intro -- Preface -- Contents -- Part I: Challenges in Patient Preparation -- 1: Challenges in Patient Preparation -- 1.1 Introduction -- 1.2 Prolonged Intervals of Fasting -- 1.3 Dietary Modifications -- 1.4 Pharmacologic Approaches -- 1.5 Conclusion -- References -- Part II: Non-ischemic Diseases -- 2: Cardiac Sarcoidosis -- 2.1 Introduction -- 2.2 Screening for Cardiac Sarcoidosis -- 2.3 Diagnosis -- 2.4 Endomyocardial Biopsy: Imaging Guidance -- 2.5 CMR for Diagnosis/CMR Imaging Protocol -- 2.6 Late Gadolinium Enhancement (LGE) -- 2.7 Imaging Myocardial Inflammation and Quantitative Tissue Characterization with CMR T1 and T2 Mapping -- 2.8 Additional CMR Findings Suggestive of Cardiac Sarcoidosis -- 2.9 Differential Diagnosis -- 2.10 Treatment: Anti-Inflammatory Therapy -- 2.11 CMR for Arrhythmogenic Risk Stratification/ICD -- 2.12 Positron Emission Tomography -- 2.13 Positron Emission Tomography with Tracers Other than 18F-FDG -- 2.14 Prognosis -- ; 2.15 Follow-up and Monitoring of Anti-Inflammatory Response -- 2.16 Hybrid PET-CMR Imaging -- 2.17 Outlook -- 2.18 Conclusion -- References -- 3: Cardiac Amyloidosis -- 3.1 Introduction -- 3.1.1 Different Phenotypes of Cardiac Amyloidosis -- 3.1.1.1 AL Amyloidosis -- 3.1.1.2 ATTR Amyloidosis -- 3.1.2 Screening for Cardiac Amyloidosis -- 3.2 Diagnosis -- 3.2.1 Endomyocardial Biopsy -- 3.2.2 Cardiac Magnetic Resonance (CMR) Imaging -- 3.2.2.1 CMR Diagnosis and Imaging Protocol -- 3.2.2.2 Late Gadolinium Enhancement (LGE) -- 3.2.2.3 Quantitative Tissue Characterization with CMR Native T1, T2 and ECV Mapping -- 3.2.2.4 Differential Diagnosis of AL vs. ATTR Amyloid -- 3.2.3 Scintigraphy -- 3.2.3.1 Bone Avid Radiotracers -- Imaging Protocols and Interpretation -- Diagnostic Accuracy -- 3.2.3.2 Innervation Radiotracers -- 3.2.4 Positron Emission Tomography (PET).; 3.2.5 Hybrid Imaging: PET/MRI -- 3.2.6 Diagnostic Algorithm for Diagnosis and Sub-Typing of Cardiac Amyloidosis -- 3.3 Treatment -- 3.4 Prognosis -- 3.5 Conclusion -- References -- Part III: Ischemic Diseases -- 4: Molecular Imaging of Vulnerable Plaque -- 4.1 Introduction -- 4.2 Biology and Pathogenesis of Atherosclerosis -- 4.2.1 History -- 4.2.2 Mechanisms of Atherosclerosis -- 4.2.2.1 Initiation of Atherosclerosis -- Vascular Endothelium and Atherosclerosis -- Hemodynamics Forces in Atherosclerosis -- Low-Density Lipoprotein Cholesterol -- Surface Adhesion Molecules -- Foam Cells Formation -- Progression of Atherosclerosis -- Smooth Muscle Cells and Atherosclerosis -- Calcification -- Plaque Neoangiogenesis -- Innate Immunity Cells in Atherosclerosis -- Adaptive Immunity in Atherosclerosis -- 4.2.3 Complication of Atherosclerosis -- 4.2.3.1 Inducible Ischemia -- 4.2.3.2 Plaque Rupture -- 4.2.3.3 Plaque Erosion -- 4.3 Metabolism of Glucose in Atherosclerosis -- 4.3.1 Glucose and Immune Cells -- 4.3.2 Imaging Inflammation in Atherosclerosis Using Glucose Metabolism -- 4.4 Targeting Chemokine Receptor Expression in Vulnerable Plaque -- 4.4.1 Technological Advancements: PET/MRI and Chemokine Receptor -- 4.4.2 Radiopharmaceutical Agents Advancements: Theragnostic and Chemochine Receptor -- 4.5 Targeting Microcalcification in Atherosclerosis -- 4.5.1 Atherosclerotic Plaque Calcium Deposition -- 4.5.2 Cardiovascular Risk Quantification -- 4.5.3 High/Risk Coronary Plaque Evaluation -- 4.5.4 Atherosclerotic Plaque Composition/Activity Assessment -- 4.6 Targeting Neovascularization in Atherosclerosis -- 4.7 Targeting SSRT-2 Receptor Expression in Atherosclerosis with DOTA-Derivatives-PET -- 4.8 Summary -- References -- 5: Post-Infarction Inflammatory Alterations -- 5.1 General Introduction.; 5.2 Biology of Ventricular Remodeling -- 5.2.1 Pathobiology of Ventricular Remodeling Post-MI -- 5.2.2 The Inflammatory Response -- 5.2.2.1 Resident Inflammatory Cells -- Mast Cells -- Macrophages -- 5.2.2.2 Infiltrating Inflammatory Cells -- Polymorphonuclear Leukocytes -- Monocytes and Macrophages -- Dendritic Cells -- T and B Lymphocytes -- 5.2.2.3 Cardiomyocytes and ECM -- 5.2.3 Animal Models to Study Post-AMI Inflammation -- 5.2.3.1 Small Animal Models -- Open Chest -- Coronary Artery Ligation -- Topical Application of FeCl3 -- Closed Chest -- Isoproterenol Injection -- 5.2.3.2 Large Animal Models -- Open Chest -- Coronary Artery Ligation -- Gradual Constriction -- Hydraulic Occluder -- Topical Application of FeCl3 -- Closed Chest -- Balloon Inflation -- Embolization -- Endothelial Electrical Injury -- 5.3 The Role of Molecular Imaging -- 5.3.1 Cardiac MRI -- 5.3.2 Single-Photon Emission Computed Tomography -- 5.3.3 Positron Emission ; Tomography -- 5.4 Imaging Targets -- 5.4.1 Metabolic Activity -- 5.4.2 Labeled Cells -- 5.4.3 Membrane Receptors -- 5.4.4 Somatostatin Receptors -- 5.4.5 Mannose Receptor -- 5.4.6 Folate Receptor -- 5.4.7 Translocator Protein -- 5.4.8 Glucagon-like Peptide-1 Receptor (GLP-1R) -- 5.4.9 Chemokine Receptors -- 5.4.10 Lymphocyte Markers -- 5.4.10.1 Adhesion Molecules -- 5.4.10.2 Extracellular (Matrix) Components -- 5.5 Hybrid Imaging: The Added Value of Hybrid Imaging -- 5.6 Concluding Remarks -- References -- Part IV: Infection -- 6: Infection: Pericarditis -- 6.1 Pericardial Anatomy -- 6.2 Pericardial Pathologies -- 6.3 Aetiology and Pathophysiology -- 6.4 Clinical Manifestations and Diagnosis -- 6.5 Computed Tomography -- 6.6 Cardiovascular Magnetic Resonance (CMR) -- 6.6.1 Typical CMR Protocol for the Evaluation of Pericardial Disease -- 6.6.2 CMR and Acute Pericarditis.; 6.6.3 CMR and Pericardial Effusions -- 6.6.4 CMR and Pericardial Constriction -- 6.6.5 Constrictive-Effusive Pericarditis -- 6.7 Molecular Imaging -- 6.8 Basics of Treatment -- 6.9 Conclusion -- References -- 7: Infection: Myocarditis -- 7.1 Introduction -- 7.2 Aetiology and Pathogenesis -- 7.3 From Acute Myocarditis to Chronic Inflammatory Cardiomyopathy and Heart Failure -- 7.4 Clinical Presentations and Diagnosis -- 7.5 Endomyocardial Biopsy -- 7.6 Cardiovascular Magnetic Resonance (CMR) -- 7.7 Infectious Inflammatory Cardiomyopathy -- 7.7.1 Idiopathic/Post-Viral Myocarditis -- 7.8 Coronavirus Disease-2019 (COVID-19) and Myocarditis -- 7.9 Non-Infectious Inflammatory Cardiomyopathy -- 7.9.1 Connective Tissue Disease -- 7.9.1.1 Systemic Lupus Erythematosus -- 7.9.1.2 Rheumatoid Arthritis -- 7.9.1.3 Systemic Sclerosis/Systemic Scleroderma -- 7.9.1.4 Behçet's Disease -- 7.9.1.5 Polyarteritis Nodosa -- 7.10 Eosinophilic Myocarditis/Endomyocardial fibrosis -- 7.10.1 EGPA -- 7.10.2 Infectious Endomyocarditis and Endomyocardial Fibrosis -- 7.10.3 Haematological -- 7.11 Drug-Induced or Toxic Myocarditis -- 7.12 Inflammatory Myositis -- 7.13 Giant Cell Myocarditis -- 7.14 Genetic Causes -- 7.15 Molecular Imaging -- 7.16 Hybrid Imaging -- 7.17 Summary -- References -- 8: Cardiac Devices Infection -- 8.1 Introduction -- 8.2 Scintigraphy in Cardiac Devices Infection -- 8.2.1 Radiolabelling of White Blood Cells with 99mTc-HMPAO or 111In-oxine -- 8.2.2 Image Acquisition -- 8.2.3 Image Interpretation -- 8.2.4 Radiolabelled WBC Scintigraphy of CIED Infection -- 8.2.5 Radiolabelled WBC Imaging of Left Ventricular Assist Devices Infection -- 8.2.6 Merits and Limitations of Radiolabelled WBC Scintigraphy in Cardiac Devices Infection: Alternative SPECT Tracers -- 8.3 FDG PET/CT Imaging of Cardiac Devices Infection.; 8.3.1 Patient Preparation -- 8.3.1.1 Suppression of Myocardial FDG Uptake -- 8.3.1.2 Withdrawal of Medications -- 8.3.2 Image Acquisition and Interpretation -- 8.3.3 FDG PET/CT Imaging of CIED Infection -- 8.3.4 FDG PET/CT Imaging of LVAD Infection -- 8.3.5 FDG PET/CT for Extra-Cardiac Disease in Patients Assessed for Cardiac Devices Infection -- 8.4 Comparative Performance of Radionuclide WBC Scintigraphy and FDG PET/CT in Cardiac Devices Infection -- 8.5 Conclusion -- References -- 9: Endocarditis -- 9.1 Introduction -- 9.2 Single Photon Emission Tomography (SPECT) -- 9.2.1 67Ga-citrate Scintigraphy -- 9.2.2 Labelled Leukocytes Scintigraphy -- 9.2.3 Other SPECT Tracers -- 9.3 Positron Emission Tomography (PET) -- 9.4 Concluding Remarks -- References.

Exploring African approaches to international law: Essays in honour of Kéba Mbaye

• Record Nr.: UNINA9910597124503321
• Autore: Viljoen Frans
• Pubbl/distr/stampa: Pretoria University Law Press, : Pretoria University Law Press (PULP), 2022
• Descrizione fisica: 1 online resource
• Soggetti: Law
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Sommario/riassunto: It is unfortunate that the idea that Africa contributes to international law, and has always done so, remains (in 2022) largely a side note, an auxiliary approach, rather than something widely accepted and deeply entrenched. It is cause for pause that this is also true in Africa itself. Exploring African approaches to international law: Essays in honour of Kéba Mbaye is a volume of essays that aims to contribute to a larger effort of imagining what possible approaches to international law Africa has adopted in the decades since the 1960s. It also recognises the legacy of the great Senegalese jurist Kéba Mbaye. Edited by Frans Viljoen, Humphrey Sipalla and Foluso Adegalu, the volume is divided into five broad thematic parts, and comprises eleven chapters. It covers the following themes: 'Kéba Mbaye in African approaches to international law', 'international legal theory', 'international human rights law', 'international environmental and criminal law' and 'teaching of international law'. This publication finds its origins in the 2017 Roundtable on African approaches to international law, held at the Centre for Human Rights, University of Pretoria. The explorations at the Roundtable on the concept of an 'African approach' to international law were taken further at the Kéba Mbaye Conference on African approaches to international law, held at the Senate Hall, University of Pretoria, in December 2018. This conference brought together around 80 students, academics, and members of civil society to address the ; many questions left unanswered by the death of Judge Mbaye, arguably Africa's greatest international law jurist of his generation. It provided a forum to continue discussions on 'African approaches to international (human rights) law', building on but rethinking and 'vernacularising' the Third World Approaches to International Law (TWAIL) approach. The contributions to this publication flow from papers presented at the conference. However, the reflections in the book extend beyond Kéba Mbaye as central figure. The result is a broad treatment of various aspects of African approaches to international law by thirteen authors (and co-authors), covering a wide range of generational, geographic and thematic backgrounds and perspectives.